Caribou Biosciences, Inc.CRBUEarnings & Financial Report
Caribou Biosciences, Inc. is a clinical-stage biotechnology company focused on developing CRISPR genome-edited cell therapies for cancers and autoimmune diseases. It operates mainly in North American and European markets, partnering with leading pharmaceutical enterprises to advance its pipeline of accessible, targeted therapeutic products for global patients.
CRBU Q4 FY2025 Key Financial Metrics
Revenue
$3.9M
Gross Profit
N/A
Operating Profit
$-28.5M
Net Profit
$-26.5M
Gross Margin
N/A
Operating Margin
-722.0%
Net Margin
-672.1%
YoY Growth
89.7%
EPS
$-0.28
Caribou Biosciences, Inc. Q4 FY2025 Financial Summary
Caribou Biosciences, Inc. reported revenue of $3.9M (up 89.7% YoY) for Q4 FY2025, with a net profit of $-26.5M (up 25.4% YoY) (-672.1% margin).
Key Financial Metrics
| Total Revenue | $3.9M |
|---|---|
| Net Profit | $-26.5M |
| Gross Margin | N/A |
| Operating Margin | -722.0% |
| Report Period | Q4 FY2025 |
Caribou Biosciences, Inc. Annual Revenue by Year
Caribou Biosciences, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $11.2M).
Caribou Biosciences, Inc. Quarterly Revenue & Net Profit History
Caribou Biosciences, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $3.9M | +89.7% | $-26.5M | -672.1% |
| Q3 FY2025 | $2.2M | +8.6% | $-27.5M | -1253.3% |
| Q2 FY2025 | $2.7M | -23.0% | $-54.1M | -2028.4% |
| Q1 FY2025 | $2.4M | -3.1% | $-40.0M | -1699.6% |
| Q4 FY2024 | $2.1M | -41.6% | N/A | N/A |
| Q3 FY2024 | $2.0M | -91.4% | $-34.7M | -1713.6% |
| Q2 FY2024 | $3.5M | -7.7% | $-37.7M | -1088.3% |
| Q1 FY2024 | $2.4M | -30.6% | $-41.2M | -1697.6% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.4M | $3.5M | $2.0M | $2.1M | $2.4M | $2.7M | $2.2M | $3.9M |
| YoY Growth | -30.6% | -7.7% | -91.4% | -41.6% | -3.1% | -23.0% | 8.6% | 89.7% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $406.8M | $372.9M | $344.3M | $313.3M | $273.7M | $220.9M | $195.0M | $175.4M |
| Liabilities | $63.5M | $62.5M | $63.1M | $60.4M | $56.4M | $54.8M | $53.1M | $53.2M |
| Equity | $343.3M | $310.5M | $281.2M | $253.0M | $217.2M | $166.1M | $141.8M | $122.2M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-37.2M | $-32.9M | $-32.7M | $-138.2M | $-36.7M | $-28.3M | $-25.2M | $-20.8M |